{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:55:34Z","timestamp":1790355334013,"version":"4.1.0"},"reference-count":72,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["F30AI181515"],"award-info":[{"award-number":["F30AI181515"]}]},{"name":"NIH","award":["R35GM151996"],"award-info":[{"award-number":["R35GM151996"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Enterovirus-D68 (EV68) continues to present as a global health issue causing respiratory illness and outbreaks associated with long-lasting neurological disease, with no antivirals or specific treatment options. The development of antiviral therapeutics, such as small-molecule inhibitors that target conserved proteins like the enteroviral 3C protease, remains to be achieved. While various 3C inhibitors have been investigated, their design does not consider the potential emergence of drug resistance mutations. For other antivirals where resistance has been a challenge, we have demonstrated that the likelihood of resistance can be minimized by designing inhibitors that leverage the evolutionary constraints of the target. Here, we characterize a series of 3C inhibitors against EV68-3C protease through enzyme inhibition, protein crystallography, and structural analysis. We have determined and analyzed three high-resolution inhibitor-bound crystal structures of EV68-3C protease, which revealed possible sites of resistance mutations, a key structural water molecule conserved during ligand binding, and the conformational flexibility of the catalytic histidine H40. This structural analysis combined with enzymatic assays provides insights for the rational design of inhibitors that are robust against resistance toward developing antiviral treatments for EV68 infections.<\/jats:p>","DOI":"10.3390\/v17010075","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:30:45Z","timestamp":1736328645000},"page":"75","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-4760","authenticated-orcid":false,"given":"Vincent N.","family":"Azzolino","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala M.","family":"Shaqra","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-791X","authenticated-orcid":false,"given":"Akbar","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-676X","authenticated-orcid":false,"given":"Nese","family":"Kurt Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-6613","authenticated-orcid":false,"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref_1","unstructured":"Haaheim, L.R., Pattison, J.R., and Whitley, R.J. (2013). Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/QCO.0000000000000187","article-title":"The epidemiology of non-polio enteroviruses: Recent advances and outstanding questions","volume":"28","author":"Parker","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","article-title":"The life cycle of non-polio enteroviruses and how to target it","volume":"16","author":"Baggen","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2016.09.013","article-title":"ICAM-5\/Telencephalin Is a Functional Entry Receptor for Enterovirus D68","volume":"20","author":"Wei","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2019.08.009","article-title":"Unmet Needs in the Evaluation, Treatment, and Recovery for 167 Children Affected by Acute Flaccid Myelitis Reported by Parents Through Social Media","volume":"102","author":"Bove","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3201\/eid2503.170897","article-title":"Acute Flaccid Myelitis Associated with Enterovirus D68 in Children, Argentina, 2016","volume":"25","author":"Carballo","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17-00310","DOI":"10.2807\/1560-7917.ES.2018.23.3.17-00310","article-title":"The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68)\u2014What is the evidence for causation?","volume":"23","author":"Dyda","year":"2018","journal-title":"Euro Surveill."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0140-6736(20)32723-9","article-title":"Acute flaccid myelitis: Cause, diagnosis, and management","volume":"397","author":"Murphy","year":"2021","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.0000000000004081","article-title":"Outcomes of Colorado children with acute flaccid myelitis at 1 year","volume":"89","author":"Martin","year":"2017","journal-title":"Neurology"},{"key":"ref_10","first-page":"245","article-title":"Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort","volume":"12","author":"Melicosta","year":"2019","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jmv.24410","article-title":"2014 outbreak of enterovirus D68 in North America","volume":"88","author":"Messacar","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3174\/ajnr.A4188","article-title":"MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak","volume":"36","author":"Maloney","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ana.24730","article-title":"Acute flaccid myelitis: A clinical review of US cases 2012\u20132015","volume":"80","author":"Messacar","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3201\/eid2208.151949","article-title":"Enterovirus D68 Infection in Children with Acute Flaccid Myelitis, Colorado, USA, 2014","volume":"22","author":"Aliabadi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1128\/JVI.01123-12","article-title":"3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"Vliegen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1128\/JVI.00787-11","article-title":"Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design","volume":"85","author":"Lu","year":"2011","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.49.2.619-626.2005","article-title":"Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor","volume":"49","author":"Binford","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1128\/AAC.00534-15","article-title":"The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir","volume":"59","author":"Lacroix","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1128\/AAC.01375-15","article-title":"Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68","volume":"59","author":"Sun","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1128\/AAC.00905-07","article-title":"In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease","volume":"51","author":"Binford","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/acsinfecdis.0c00120","article-title":"Enterovirus D68 Antivirals: Past, Present, and Future","volume":"6","author":"Hu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2013.03.003","article-title":"Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds","volume":"98","author":"Rhoden","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: Real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets\u2014And the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Brown, D.M., Zhang, Y., and Scheuermann, R.H. (2020). Epidemiology and Sequence-Based Evolutionary Analysis of Circulating Non-Polio Enteroviruses. Microorganisms, 8.","DOI":"10.3390\/microorganisms8121856"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Azzolino, V.N., Shaqra, A.M., Ali, A., Kurt Yilmaz, N., and Schiffer, C.A. (2024). Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance. Viruses, 16.","DOI":"10.3390\/v16091419"},{"key":"ref_34","first-page":"1333","article-title":"Combating susceptibility to drug resistance: Lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","article-title":"Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding","volume":"107","author":"Romano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular Basis for Drug Resistance in HIV-1 Protease","volume":"2","author":"Ali","year":"2010","journal-title":"Viruses"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10409238.2019.1568962","article-title":"Resistance outside the substrate envelope: Hepatitis C NS3\/4A protease inhibitors","volume":"54","author":"Ozen","year":"2019","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00172-20","DOI":"10.1128\/mBio.00172-20","article-title":"Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3\/4A Protease Inhibitors","volume":"11","author":"Matthew","year":"2020","journal-title":"mBio"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Romano, K.P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L.M., Silver, C., Cao, H., Newton, A., and Petropoulos, C.J. (2012). The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002832"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes","volume":"10","author":"Nalivaika","year":"2002","journal-title":"Structure"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: A comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/355472a0","article-title":"Free R value: A novel statistical quantity for assessing the accuracy of crystal structures","volume":"355","author":"Brunger","year":"1992","journal-title":"Nature"},{"key":"ref_51","unstructured":"(2019). Schr\u00f6dinger Release 2019-2. Desmond Molecular Dynamics System, D.E. Shaw Research, Schr\u00f6dinger."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1021\/acs.biochem.1c00414","article-title":"Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode","volume":"60","author":"Lockbaum","year":"2021","journal-title":"Biochemistry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acschembio.9b00370","article-title":"Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance","volume":"14","author":"Henes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1021\/acs.jctc.8b00097","article-title":"Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease","volume":"14","author":"Leidner","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"ref_58","unstructured":"(2019). Schr\u00f6dinger Release 2019-2. Maestro-Desmond Interoperability Tools, Schr\u00f6dinger."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.jctc.0c01244","article-title":"Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning","volume":"17","author":"Leidner","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3\/4A protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1021\/acschembio.0c00975","article-title":"Inhibiting HTLV-1 Protease: A Viable Antiviral Target","volume":"16","author":"Lockbaum","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/jm980537b","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/jm030166l","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics","volume":"46","author":"Dragovich","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/jm9805384","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/jm980068d","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/jm9800696","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0968-0896(99)00005-X","article-title":"Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides","volume":"7","author":"Dragovich","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1107\/S0907444913002862","article-title":"Structures of Enterovirus 71 3C proteinase (strain E2004104-TW-CDC) and its complex with rupintrivir","volume":"69","author":"Wu","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1128\/JVI.05062-11","article-title":"Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93","volume":"85","author":"Costenaro","year":"2011","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1006\/jmbi.1997.1306","article-title":"Refined X-ray crystallographic structure of the poliovirus 3C gene product","volume":"273","author":"Mosimann","year":"1997","journal-title":"J. Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12250-020-00196-4","article-title":"Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design","volume":"35","author":"Yuan","year":"2020","journal-title":"Virol. Sin."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:24:57Z","timestamp":1759919097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["v17010075"],"URL":"https:\/\/doi.org\/10.3390\/v17010075","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}